inobrodib + Pd (InoPd)
Relapsed/Refractory Multiple Myeloma
Phase 1/2Active
Key Facts
About CellCentric
CellCentric is a UK-based, private biotech founded in 2004, focused on inhibiting the epigenetic targets p300 and CBP for oncology. Its lead candidate, inobrodib, is a first-in-class, oral small molecule currently in clinical trials for multiple myeloma, with promise in other cancers. The company emphasizes a collaborative R&D model and aims to deliver a convenient, community-based treatment option to improve patient access and quality of life. CellCentric is led by an experienced team of drug developers and is backed by investor directors on its board.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Aplidin (plitidepsin) | PharmaMar | Approved (Conditional - AU) |
| TECVAYLI + DARZALEX FASPRO | johnson-and-johnson-innovative-medicine | Approved |
| Linvoseltamab | Regeneron | Phase 3 |
| Blenrep (belantamab mafodotin) | GSK | Phase III |
| CAR T-Cell Therapy Program | Dr. Reddy's Laboratories | Development |
| HDP-101 | Heidelberg Pharma | Phase I/IIa |
| CT053 | CARsgen Therapeutics | Phase Ib/II |
| CT059 | CARsgen Therapeutics | Phase I |
| P-BCMA-ALLO1 | Poseida Therapeutics | Phase 1 |
| P-BCMA-101 | Poseida Therapeutics | Phase 1/2 |
| ABBV-383 | AbbVie | Phase 1 |
| bri-cel (BAY 2413334) | Bayer | Phase I |